ASH 2023 | Tazemetostat + lenalidomide & rituximab vs. lenalidomide & rituximab in patients with R/R FL
Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the benefit of combining tazemetostat with lenalidomide and rituximab in the treatment of relapsed/refractory (R/R) follicular lymphoma (FL) by comparing outcomes for those treated with this triplet combination in the SYMPHONY-1 trial (NCT04224493), to an external control arm of patients treated with lenalidomide and rituximab after at least one prior line of systemic therapy. The overall response rate (ORR) was higher in those treated with the triplet, though inference is limited due to small sample sizes and indirect comparison methods. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: ADC Therapeutics, Bristol Myers Squibb/Celgene, Caribou Biosciences, AbbVie, DeNovo, Daiichi Sankyo, Genentech, Inc., Genmab, Gilead/Kite, Janssen, Merck, Novartis, Takeda, Regeneron, AstraZeneca, Gilead Sciences/Kite Pharma
Research Funding: Bristol Myers Squibb/Celgene, Caribou Biosciences, Daiichi Sankyo, Genentech, Inc., Genmab, Gilead/Kite, Janssen, Merck, Novartis, Takeda, Gilead Sciences/Kite Pharma
